Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Lucio Crinò et al.|New England Journal of Medicine|2013Cited by 3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyDaniel R. Gomez, John V. Heymach, Chad Tang et al.|Journal of Clinical Oncology|2019Cited by 1.3k
Response assessment criteria for brain metastases: proposal from the RANO groupNancy U. Lin, Patrick Y. Wen, Eudocia Q. Lee et al.|The Lancet Oncology|2015Cited by 1.1k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R. Gomez, John V. Heymach, George R. Blumenschein et al.|The Lancet Oncology|2016Cited by 1.1k